Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Quanterix Corp

Healthcare US QTRX

5.02USD
-0.08(1.57%)

Last update at 2026-03-10T20:00:00Z

Day Range

4.925.28
LowHigh

52 Week Range

14.2629.70
LowHigh

Fundamentals

  • Previous Close 5.10
  • Market Cap632.22M
  • Volume838350
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-42.55000M
  • Revenue TTM125.98M
  • Revenue Per Share TTM3.33
  • Gross Profit TTM 46.81M
  • Diluted EPS TTM-0.97

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -96.63500M -57.72400M -31.90600M -40.98300M -31.04500M
Minority interest - - - - -
Net income -96.70000M -57.68800M -31.53000M -40.79600M -31.04500M
Selling general administrative 1.28M 92.34M 59.59M 52.25M 33.78M
Selling and marketing expenses 92.00M - - - -
Gross profit 46.24M 61.73M 48.18M 26.84M 17.98M
Reconciled depreciation 5.35M 4.85M 4.31M 3.01M 1.35M
Ebit -72.35700M -63.43700M -35.89600M -41.60000M -32.44300M
Ebitda -43.01000M -58.58600M -31.58400M -41.61000M -31.09100M
Depreciation and amortization 29.35M 4.85M 4.31M -0.01000M 1.35M
Non operating income net other -0.06200M 1.26M -0.04900M -0.01000M -0.00700M
Operating income -72.35700M -58.58600M -31.58400M -41.60000M -31.55000M
Other operating expenses 177.31M 169.14M 117.96M 98.33M 68.72M
Interest expense 5.13M 0.40M 0.27M 0.63M 0.05M
Tax provision 0.07M -0.03600M -0.37600M -0.18700M 0.03M
Interest income - - - 0.63M 0.05M
Net interest income 5.13M -0.40300M -0.27300M 0.63M 0.05M
Extraordinary items - - - - -
Non recurring 29.35M - - - -
Other items - - - - -
Income tax expense 0.07M -0.03600M -0.37600M -0.18700M 0.03M
Total revenue 104.95M 110.56M 86.38M 56.73M 37.63M
Total operating expenses 118.59M 120.31M 79.77M 68.44M 49.07M
Cost of revenue 58.72M 48.83M 38.20M 29.90M 19.65M
Total other income expense net -24.27800M 0.86M -0.32200M 0.62M -0.00700M
Discontinued operations - - - - -
Net income from continuing ops -96.70000M -57.68800M -31.53000M -40.79600M -31.53600M
Net income applicable to common shares -96.70000M -57.68800M -31.53000M -40.79600M -31.53600M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 425.01M 434.20M 501.53M 271.05M 169.95M
Intangible assets 6.03M 7.52M 10.53M 13.72M 14.31M
Earning assets - - - - -
Other current assets 9.29M 6.86M 6.51M 5.98M 2.14M
Total liab 78.08M 75.26M 60.58M 64.92M 41.29M
Total stockholder equity 346.93M 358.94M 440.95M 206.12M 128.66M
Deferred long term liab - - - - -
Other current liab 19.70M 15.79M 19.98M 18.68M 9.28M
Common stock 0.04M 0.04M 0.04M 0.03M 0.03M
Capital stock 0.04M 0.04M 0.04M 0.03M 0.03M
Retained earnings -434.49600M -402.16200M -305.46200M -247.77400M -216.24400M
Other liab - 2.88M 3.13M 3.23M 13.87M
Good will - 0.00000M 9.63M 10.46M 9.35M
Other assets - 3.90M 2.96M 13.35M 1.58M
Cash 174.42M 338.74M 396.46M 181.58M 109.16M
Cash and equivalents - - - - -
Total current liabilities 38.46M 30.96M 36.98M 39.80M 19.83M
Current deferred revenue 9.47M 8.64M 6.36M 5.42M 4.70M
Net debt -132.95800M -294.63600M -374.57300M -150.78600M -101.49300M
Short term debt 4.24M 2.69M 1.43M 8.91M 0.07M
Short long term debt - - - 7.67M 0.07M
Short long term debt total 41.46M 44.10M 21.89M 30.80M 7.66M
Other stockholder equity 783.14M 763.69M 745.94M 451.43M 345.03M
Property plant equipment - 20.16M 29.45M 13.91M 12.05M
Total current assets 378.39M 381.40M 448.95M 219.60M 132.66M
Long term investments - - - - 0.50M
Net tangible assets - 358.94M 420.79M 206.12M 105.00M
Short term investments 146.90M - - - -
Net receivables 25.41M 19.02M 23.79M 17.18M 10.91M
Long term debt - - - - 7.59M
Inventory 22.36M 16.79M 22.19M 14.86M 10.46M
Accounts payable 5.05M 3.84M 9.21M 6.80M 5.78M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1.75700M -2.62300M 0.44M 2.43M -0.15300M
Additional paid in capital - - - - -
Common stock total equity - 0.04M 0.04M 0.03M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - -402.16200M -305.46200M -247.77400M -216.24400M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -4.00800M 3.90M 2.96M 1.36M 1.58M
Deferred long term asset charges - - - - -
Non current assets total 46.62M 52.80M 52.57M 51.44M 37.29M
Capital lease obligations 41.46M 44.10M 21.89M 23.12M -
Long term debt total - - - - 7.59M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -11.20600M -6.33800M -0.62600M -25.37600M -0.15000M
Change to liabilities -6.72900M 4.57M 7.21M 10.58M 0.57M
Total cashflows from investing activities -11.20600M -6.33800M -0.62600M -25.37600M -5.45400M
Net borrowings - -7.73800M -0.07500M -0.05000M -1.92900M
Total cash from financing activities 2.31M 270.80M 96.24M 116.20M -0.07800M
Change to operating activities -5.70900M -1.11900M 2.40M 11.27M -0.46000M
Net income -96.70000M -57.68800M -31.53000M -40.79600M -31.53600M
Change in cash -57.70500M 216.46M 72.40M 64.75M -34.25300M
Begin period cash flow 399.04M 182.58M 110.18M 45.43M 79.68M
End period cash flow 341.34M 399.04M 182.58M 110.18M 45.43M
Total cash from operating activities -48.27200M -47.90700M -23.36500M -26.18700M -28.72100M
Issuance of capital stock 0.00000M 269.72M 91.40M 112.55M 0.00000M
Depreciation 5.35M 4.85M 4.31M 3.01M 1.35M
Other cashflows from investing activities 0.52M 7.28M 3.30M -14.52900M -3.78600M
Dividends paid - - - - -
Change to inventory 5.39M -8.09000M -5.11900M -3.44700M -1.60300M
Change to account receivables 5.16M -6.85300M -6.24000M -3.36500M -0.98300M
Sale purchase of stock 2.31M 278.53M 96.31M 116.25M -0.02000M
Other cashflows from financing activities 2.31M 8.81M 4.91M 3.70M 1.87M
Change to netincome 40.29M 16.34M 10.36M 6.62M 5.04M
Capital expenditures 11.73M 13.62M 3.93M 10.85M 1.52M
Change receivables 5.16M -6.85300M -6.24000M -3.36500M -0.98300M
Cash flows other operating -1.02800M -1.04300M -2.35900M 1.22M -1.56100M
Exchange rate changes - - - - -
Cash and cash equivalents changes -57.16700M 216.55M 72.25M 64.63M -34.25300M
Change in working capital 2.07M -12.18600M -7.47000M 4.37M -3.57700M
Stock based compensation 15.44M 15.97M 10.10M 6.39M 4.88M
Other non cash items 25.79M 0.34M 0.81M 0.70M 0.17M
Free cash flow -59.99800M -61.52300M -27.29500M -37.03400M -30.23900M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
QTRX
Quanterix Corp		 -0.08 1.57% 5.02 - - 5.71 2.01 3.46 -10.5313
ABT
Abbott Laboratories		 -2.1 1.86% 110.55 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -7.27 1.99% 358.65 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -1.45 1.59% 89.89 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -1.94 2.70% 69.96 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Quanterix Corp

Building 1, Billerica, MA, United States, 01821

Key Executives

Name Title Year Born
Dr. Masoud Toloue Ph.D. Pres, CEO & Director 1980
Dr. David R. Walt Ph.D. Co-Founder, Chairman of Scientific Advisory Board & Independent Director 1953
Mr. Michael A. Doyle CFO & Treasurer 1956
Mr. Bruce J. Bal VP of Operations, Service & Quality 1959
Mr. Daniel Pikora Chief Operating Officer 1975
Dr. David C. Duffy Ph.D. Sr. VP of R&D and CTO 1971
David Panzerella VP of Sales NA
Dr. Mark T. Roskey Ph.D. Sr. VP of Strategic Partnerships 1960
Ms. Mary Ellen Cortizas VP of Laboratory Services & CRO NA
Dr. Masoud Toloue Ph.D. President, CEO & Director 1981

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.